CAPR — Capricor Therapeutics, Inc.
$9.53
$-0.71 (-6.93%)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Market Cap
$554.09M
Forward P/E
-6.7x
52-Week Range
N/A
CAPR Price History
Revenue vs. Net Income
$0
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$81.5M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-31.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
7.1x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
6.9%
CapEx · FY2024
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+32.0%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
